Skip to content

Depression: all studies

Page 125 of 1,035: studies 1,241 to 1,250 of 10,348, newest first. Back to the depression overview

Research

Understanding the variability in ketamine’s efficacy in managing treatment-resistant depression

Discover Psychology November 3, 2024 Joshua W. Bryan 3 citations

Abstract Ketamine, often associated with its frequent illicit recreational use, is renowned as an approved alternative for treatment-resistant depression. This paper evaluates the mechanism of ketamine’s role in treating depression, emphasising its positive safety profile and acute onset of action. Ketamine’s mechanism of action involves antagonism of N-methyl-D-Aspartate (NMDA) receptors,...

Investigating change in the ability to decentre and depressive symptomatology over the course of a six-month mindfulness-based intervention in patients with persistent depression.

Psychiatry Research November 1, 2024 Jonathan Hamilton, Thorsten Barnhofer 2 citations

Mindfulness-based interventions (MBIs) for depression use regular mindfulness practice as a means of helping patients build skills that allow them to respond more adaptively to negative mood. Although effects of practice are assumed to accumulate over time, little is known about the trajectories of change in skills and symptoms beyond the duration of standard eight-week interventions....

Glutamatergic Modulators for Major Depression from Theory to Clinical Use.

CNS Drugs November 1, 2024 Roger S McIntyre, Rakesh Jain 58 citations

Major depressive disorder (MDD) is a chronic, burdensome, highly prevalent disease that is characterized by depressed mood and anhedonia. MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates. In the past 2 decades, a promising target emerged to improve patient outcomes in depression treatment:...

DOI: 10.1007/s40263-024-01114-y (opens in new tab) Full text (opens in new tab) Depression treatment Mental health Antidepressants Brain chemistry

The effect of a subclinical dose of esketamine on depression and pain after cesarean section: A prospective, randomized, double-blinded controlled trial.

Medicine November 1, 2024 Xiangqian Wan, Ming Li, Xiantao Li et al. 8 citations

The aim of this randomized, double-blind placebo-controlled clinical trial was to study the effects of subclinical doses of esketamine on postpartum depression and pain following elective cesarean sections. This randomized, double-blind placebo-controlled trial included 150 pregnant women undergoing elective cesarean sections. After umbilical cord clamping, participants received either...

DOI: 10.1097/MD.0000000000040295 (opens in new tab) Full text (opens in new tab) Pain management Obstetrics Anesthesia Cesarean section +1

Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies.

The International Journal of Neuropsychopharmacology November 1, 2024 Randall L. Morrison, Jaskaran Singh, Ella Daly et al. 9 citations

While esketamine is effective in treatment-resistant depression (TRD), detailed information about the effect of esketamine on cognition is relatively scarce. This analysis assessed the effect of short-term (3 double-blind [DB] studies: DB1, DB2, and DB4) or long-term maintenance treatment (DB3) with esketamine nasal spray (ESK) compared with a placebo (PBO) combined with active-comparator, on...

DOI: 10.1093/ijnp/pyae046 (opens in new tab) Full text (opens in new tab) Esketamine Cogstate battery test Randomized controlled trials Depression treatment +7

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.

The British Journal of Psychiatry November 1, 2024 Gero Joks, Steve Su, Jarrad King

Regarding the article, 'Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial', we commend Loo et al for undertaking the Ketamine for Adult Depression Study (KADS). In the interest of ensuring that accurate and balanced information is presented to healthcare...

DOI: 10.1192/bjp.2024.79 (opens in new tab) Full text (opens in new tab) Major depressive disorder Depression/mental health/mental illness Ketamine/esketamine/psychedelics Treatment-resistant depression/trd/refractory depression

Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression.

Neuropsychopharmacology November 1, 2024 Ruth H Asch, Chadi G. Abdallah, Richard E. Carson et al. 11 citations

The development of novel radiotracers for Positron Emission Tomography (PET) imaging agents targeting the synaptic vesicle glycoprotein 2 A (SV2A), an integral glycoprotein present in the membrane of all synaptic vesicles throughout the central nervous system, provides a method for the in vivo quantification of synaptic density. This is of particular interest in neuropsychiatric disorders given...

Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis.

CNS Spectrums October 31, 2024 Sabrina Wong, Gia Han Le, Angela T H Kwan et al. 10 citations

Postpartum depression (PPD), now referred to as perinatal depression, is a prevalent and debilitating mood disorder that reduces health-related quality of life (HRQoL) and psychosocial functioning. Esketamine, which is efficacious in adults with treatment-resistant depression and individuals with depression and suicidality, is also analgesic in pain management during childbirth labour. Herein,...

DOI: 10.1017/S1092852924000452 (opens in new tab) Full text (opens in new tab) Spravato Mdd prevention Perinatal depression Postpartum depression ppd +4

Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials

Journal of Psychopharmacology October 31, 2024 Sepehr Aghajanian, Arman Shafiee, Samira Parvizi Omran et al. 12 citations

Background: Due to the unsatisfactory therapeutic effects of current antidepressants, research has been launched into alternative treatment approaches, such as the administration of psychedelics. Psilocybin, a classic hallucinogen, has been shown to exert considerable positive influence on depression symptoms through its serotonergic and glutamatergic effects. This systematic review and...

Mindfulness-based cognitive therapy for depression.

Industrial Psychiatry Journal October 29, 2024 Dolly Kumari, Nikhar Satyapal

Dear Editor, Mindfulness gives a sight to be aware of the present moment-by-moment sensations, emotions, thoughts, and experiences with a non-judgmental attitude.[1,2] Practitioners of mindfulness learn to live in the present moment and not travel in the past or future with their emotional interpretations of events which leads to pain in life. This technique is helpful in patient groups to...